quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:32:33·3h
ANALYSTRating
InflaRx N.V. logo

Oppenheimer resumed coverage on InflaRx with a new price target

IFRX· InflaRx N.V.
Health Care
Original source

Companies

  • IFRX
    InflaRx N.V.
    Health Care

Recent analyst ratings

  • Apr 24UpdateOppenheimer$5.00
  • Dec 3UpdateLeerink Partners$2.00
  • Sep 2UpdateH.C. Wainwright$6.00
  • May 29UpdateRaymond James$2.00
  • Apr 29UpdateCantor Fitzgerald$10.00
  • Apr 5UpdateGuggenheim$8.00

Related

  • SEC19h
    SEC Form 6-K filed by InflaRx N.V.
  • SEC14d
    SEC Form 6-K filed by InflaRx N.V.
  • PR15d
    InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
  • SEC21d
    SEC Form 6-K filed by InflaRx N.V.
  • PR24d
    InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium
  • SEC35d
    SEC Form 20-F filed by InflaRx N.V.
  • SEC36d
    SEC Form 6-K filed by InflaRx N.V.
  • PR36d
    InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022